Targets › REN
1 program from 1 company in 1 trial: 1 Phase 2; Genitourinary; next expected readout Dec 2029.
Renin is a highly specific endopeptidase, whose only known function is to generate angiotensin I from angiotensinogen in the plasma, initiating a cascade of reactions that produce an elevation of blood pressure and increased sodium retention by the kidney. (UniProt, P00797)
Open in Phaseline: the race on REN, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Region Skane | Aliskiren Renin inhibitor | REN | Phase 2 | C3 Glomerulopathy | Dec 2029 |
C3 Glomerulopathy (1)
small molecule (1)
Region Skane (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.